Form 4: Vaxcyte CEO Grant Pickering Exercises Options and Sells Shares Under 10b5-1 Plan

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 23, 2024, Grant Pickering, the CEO of Vaxcyte, Inc., exercised stock options to acquire 15,000 shares of common stock at a price of $2.03 per share.
• He then sold 6,211 shares at a weighted-average price of $68.843 and 8,789 shares at a weighted-average price of $69.84.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Pickering directly owns 477,847 shares of Vaxcyte common stock.
• He also indirectly owns 146,054 shares through a trust for his daughter and 146,054 shares through a trust for his son.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the executive's confidence in the company.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

Executive stock transactions are common and closely monitored, especially in the biotech industry where stock options are a significant part of compensation. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry often include stock options and restricted stock units.
• The use of Rule 10b5-1 trading plans is a standard practice among executives to manage their stock holdings and avoid potential insider trading accusations.
• Comparing Pickering's stock ownership and trading activity to those of CEOs at comparable biotech companies (e.g., Moderna, BioNTech) would provide further context.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential dilution from option exercises and the selling pressure from the share sales.

Key Dates